Skip to content
← Catalog

J Hematol Oncol 2026 · CAR-Macrophage review · Chen/Lin

"Chimeric antigen receptor macrophage (CAR-M) therapy has emerged as a highly promising novel platform in solid tumor immunotherapy. Leveraging its inherent tumor-homing capacity, potent phagocytic function, and potential to remodel the tumor microenvironment (TME), CAR-M offers…

Type
paper
Domain
oncology
Grade
conference
License
LIGHT_HOPE_proprietary
Provenance
m622_verify_wave_3_2026-05-16
evidence_grade
A
category
car_macrophage_review
status
verified
instance_tag
sunvax-antibody-2025
clinical_claim_softening
"review · preclinical/early-clinical CAR-M landscape · not intended to guide individual patient treatment choices"
journal
Journal of Hematology & Oncology
year
2026
authors
Yizhao Chen,Ning Lin
abstract_snippet
"Chimeric antigen receptor macrophage (CAR-M) therapy has emerged as a highly promising novel platform in solid tumor immunotherapy. Leveraging its inherent tumor-homing capacity, potent phagocytic function, and potential to remodel the tumor microenvironment (TME), CAR-M offe
pmid
41964040
doi
10.1186/s13045-026-01792-9
View at source ↗

Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.